Event-Driven Stocks

GILEAD SCIENCES, INC.

GILDNasdaq

Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 5 gooddetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$29.44B$28.75B$27.12B$27.28B$27.30B$24.69B
Operating income$10.02B$1.66B$7.61B$7.33B$9.92B$4.07B
Net income$8.51B$480.0M$5.67B$4.59B$6.22B$123.0M
Total assets$59.02B$58.99B$62.13B$63.17B$67.95B$68.41B
Total liabilities——————
Equity$22.70B$19.33B$22.83B$21.24B$21.07B$18.20B
EPS (diluted)$6.78$0.38$4.50$3.64$4.93$0.10
Shares out.1.25B1.25B1.25B1.25B1.26B1.26B

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
34.0%
Net margin
28.9%
Return on equity
37.5%
Return on assets
14.4%
Return on capital (ROCE)
21.2%
Liabilities / assets
—
Debt / equity
—
Book value / share
$18.23
Revenue growth (YoY)
2.4%
Net income growth (YoY)
1672.9%

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Accruals / assets
−2.6%clean
Piotroski F-Score
7/8strong

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
87
/ 100
Profitability 100Growth 100Catalyst 33Earnings quality 100Financial strength 100

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 5 good
  • Operating margin is positive
  • Strong return on equity (>15%)
  • Revenue is growing year-over-year
  • Positive operating cash flow
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

FDA-approved drugs

openFDA · most recent
  • ATRIPLAJul 12, 2006

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 202623.1M3.6+0.4%
Apr 30, 202623.1M4.1+1.3%
Apr 15, 202622.8M4.7+5.7%
Mar 31, 202621.5M3.2+7.7%
Mar 13, 202620.0M3.4+8.3%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (11)